Barclays began coverage on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a research report sent to investors on Tuesday morning, 24/7 WallStreet reports. The firm issued an overweight rating and a $19.00 price objective on the specialty pharmaceutical company’s stock.
AMAG has been the topic of a number of other research reports. Cantor Fitzgerald reiterated a hold rating and issued a $14.00 target price (down previously from $17.00) on shares of AMAG Pharmaceuticals in a research note on Thursday, March 14th. BidaskClub lowered AMAG Pharmaceuticals from a sell rating to a strong sell rating in a research note on Thursday, March 7th. ValuEngine downgraded AMAG Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Friday, February 15th. Zacks Investment Research downgraded AMAG Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 20th. Finally, SunTrust Banks assumed coverage on AMAG Pharmaceuticals in a research report on Tuesday, March 19th. They set a hold rating on the stock. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $18.78.
AMAG stock opened at $9.29 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.13 and a current ratio of 2.30. AMAG Pharmaceuticals has a twelve month low of $9.02 and a twelve month high of $26.10. The firm has a market capitalization of $312.34 million, a price-to-earnings ratio of -2.39 and a beta of 0.48.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.77). AMAG Pharmaceuticals had a negative return on equity of 26.33% and a negative net margin of 30.90%. The business had revenue of $75.80 million during the quarter, compared to analysts’ expectations of $90.13 million. During the same quarter in the previous year, the business earned ($1.59) EPS. The business’s revenue for the quarter was down 35.4% on a year-over-year basis. Sell-side analysts predict that AMAG Pharmaceuticals will post -5.72 earnings per share for the current fiscal year.
In other news, insider Julie Krop purchased 10,000 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were acquired at an average price of $9.91 per share, with a total value of $99,100.00. Following the transaction, the insider now owns 81,399 shares of the company’s stock, valued at $806,664.09. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Elizabeth Scott Bolgiano purchased 5,000 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were purchased at an average cost of $10.93 per share, for a total transaction of $54,650.00. Following the transaction, the insider now directly owns 74,847 shares in the company, valued at approximately $818,077.71. The disclosure for this purchase can be found here. Insiders have bought a total of 25,000 shares of company stock worth $260,750 in the last three months. Corporate insiders own 4.90% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Birchview Capital LP bought a new stake in AMAG Pharmaceuticals during the fourth quarter valued at about $152,000. Monashee Investment Management LLC bought a new stake in AMAG Pharmaceuticals during the fourth quarter valued at about $2,506,000. Great West Life Assurance Co. Can boosted its position in AMAG Pharmaceuticals by 12.3% during the fourth quarter. Great West Life Assurance Co. Can now owns 44,924 shares of the specialty pharmaceutical company’s stock valued at $629,000 after purchasing an additional 4,919 shares in the last quarter. Two Sigma Investments LP boosted its position in AMAG Pharmaceuticals by 129.3% during the fourth quarter. Two Sigma Investments LP now owns 250,589 shares of the specialty pharmaceutical company’s stock valued at $3,806,000 after purchasing an additional 141,286 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in AMAG Pharmaceuticals by 18.9% during the fourth quarter. Rhumbline Advisers now owns 102,741 shares of the specialty pharmaceutical company’s stock valued at $1,561,000 after purchasing an additional 16,305 shares in the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Recommended Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.